Drug intelligence / Profile preview

Orlenzia

Development stage: Unknown
Lead developer: Ambrezzia Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Orlenzia is an oral small molecule medication developed by Ambrezzia Pharmaceuticals for the treatment of obesity and diabetic obesity. It contains orlistat, a potent and specific long-acting inhibitor of gastrointestinal lipases. The drug works by forming a covalent bond with the active serine site of gastric and pancreatic lipases in the lumen of the stomach and small intestine. This inactivation prevents the enzymes from hydrolyzing dietary fat (triglycerides) into absorbable free fatty acids and monoglycerides, thereby reducing caloric absorption and promoting weight loss. Orlenzia is specifically positioned as a weight management solution for obese diabetic patients.

Brand names: Orlenzia
Other names: orlistat

Targets

LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on Orlenzia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orlenzia.

Explore the full profile